



## Evaluation of P-glycoprotein function at the blood–brain barrier using [<sup>18</sup>F]MC225-PET

Pascalie Mossel<sup>1</sup> · Lara Garcia Varela<sup>1</sup> · Wejdan M. Arif<sup>1,2</sup> · Chris W. J. van der Weijden<sup>1</sup> · Hendrikus H. Boersma<sup>1</sup> · Antoon T. M. Willemsen<sup>1</sup> · Ronald Boellaard<sup>1,3</sup> · Philip H. Elsinga<sup>1</sup> · Ronald J. H. Borra<sup>1</sup> · Nicola A. Colabufo<sup>4</sup> · Jun Toyohara<sup>5</sup> · Peter Paul de Deyn<sup>6,7,8</sup> · Rudi A. J. O. Dierckx<sup>1</sup> · Adriaan A. Lammertsma<sup>1,3</sup> · Anna L. Bartels<sup>7</sup> · Gert Luurtsema<sup>1</sup>

Received: 7 March 2021 / Accepted: 19 May 2021 / Published online: 5 June 2021  
© The Author(s) 2021

P-glycoprotein (P-gp) is an ATP-dependent efflux transporter located at the blood–brain barrier (BBB), involved in the transport of a variety of neurotoxic substances out of the brain. Alterations in P-gp function play an essential role in the pathophysiological mechanisms underlying neurodegenerative disorders. The most widely used tracer to measure BBB P-gp function in vivo is (*R*)-[<sup>11</sup>C]verapamil [1]. However, (*R*)-[<sup>11</sup>C]verapamil is an avid P-gp substrate, and its low uptake hampers the measurement of increases in P-gp function. In order to overcome this limitation, [<sup>18</sup>F]MC225 was developed as a novel PET tracer to measure P-gp function in vivo. [<sup>18</sup>F]MC225 is a weaker P-gp substrate and has shown higher brain uptake than (*R*)-[<sup>11</sup>C]verapamil at baseline in preclinical studies [2]. This may facilitate the evaluation of both increases and decreases in P-gp function.

In addition, the longer half-life of fluorine-18 enables the use of [<sup>18</sup>F]MC225 in centers without an onsite cyclotron.


These standardized uptake value (SUV) images show one of the first [<sup>18</sup>F]MC225 PET brain scans in a healthy human subject in both unblocked (A) and blocked (B) P-gp state. Blocking was achieved by continuous intravenous administration of the specific P-gp inhibitor cyclosporin (2.5 mg/kg/h), starting 30 min prior to the scan. Quantitatively, the whole brain grey matter volume of distribution  $V_T$  changed from  $V_T = 4.38$  at baseline to  $V_T = 5.48$  after cyclosporin administration, showing higher uptake at baseline levels compared with previously described data of [<sup>11</sup>C]verapamil ( $V_T = 1.28$  at baseline,  $V_T = 2.00$  after P-gp inhibition) [3], illustrating [<sup>18</sup>F]MC225 as a promising tracer to measure BBB P-gp function in humans.

This article is part of the Topical Collection on Image of the month.

✉ Gert Luurtsema  
g.luurtsema@umcg.nl

- <sup>1</sup> Department of Nuclear Medicine and Molecular Imaging, University of Groningen, University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, The Netherlands
- <sup>2</sup> College of Applied Medical Science, Department of Radiological Sciences, King Saud University, Riyadh, Saudi Arabia
- <sup>3</sup> Department of Radiology & Nuclear Medicine, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1117, Amsterdam, The Netherlands
- <sup>4</sup> Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, Bari, Italy

- <sup>5</sup> Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, 35-2 Sakaecho, Itabashiku, Tokyo 1730015, Japan
- <sup>6</sup> Department of Biomedical Sciences, Neurochemistry and Behaviour, Institute Born-Bunge (IBB), University of Antwerp, Wilrijk, Antwerp, Belgium
- <sup>7</sup> Department of Neurology, Alzheimer Center Groningen, University Medical Center Groningen (UMCG) and University of Groningen, Hanzeplein 1 9713, GZ, Groningen, The Netherlands
- <sup>8</sup> Faculty of Medicine and Health Sciences, University of Antwerp, Wilrijk, Antwerp, Belgium



**Funding** Open access funding provided by University Medical Center Groningen (UMCG). This study was funded by Siemens Healthineers (grant number C00227575 17).

## Declarations

**Ethics approval and informed consent** All procedures performed involving the human participant were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from the patient.

**Competing interests** GL received a research grant from Siemens Healthineers for appointing a PhD candidate. The other authors declare no competing interests.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not

permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

## References

1. Lubberink M, Luurtsema G, van Berckel BN, Boellaard R, Toornvliet R, Windhorst AD, et al. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (*R*)-[ $^{11}\text{C}$ ]verapamil and PET. *J Cereb Blood Flow Metab*. 2007. <https://doi.org/10.1038/sj.jcbfm.9600349>.
2. García-Varela L, Arif WM, Vázquez García D, Kakiuchi T, Ohba H, Harada N, et al. Pharmacokinetic modeling of [ $^{18}\text{F}$ ]MC225 for quantification of the P-glycoprotein function at the blood-brain barrier in non-human primates with PET. *Mol. Pharm*. 2020 <https://doi.org/10.1021/acs.molpharmaceut.0c00514>
3. Muzi M, Mankoff DA, Link JM, Shoner S, Collier AC, Sasongko L, et al. Imaging of cyclosporine inhibition of P-glycoprotein activity using  $^{11}\text{C}$ -verapamil in the brain: studies of healthy humans. *J Nucl Med*. 2009. <https://doi.org/10.2967/jnumed.108.059162>.

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.